

**Mitchell W. Smith, D.O., M.S., FAAAAI**  
**The Indiana Clinical Trials Center, P.C.**  
**2155 E. Main Street, Suite 200**  
**Plainfield, Indiana 46168**  
**(317) 837-6082**

**PROFESSIONAL EXPERIENCE:**

5/2019 – Present	Principal Investigator/Sub-Investigator The Indiana Clinical Trials Center, PC Plainfield, Indiana
6/2015 – Present	Physician Partner, Allergist and Clinical Immunologist Central Indiana Allergy Greenwood, Indiana
4/2014 – 12/2018	Consultant, US Precision Program Development of Asthma Risk Screening Tools AstraZeneca
2/2014 – 4/2015	Urgent Care Physician Franciscan St. Francis Immediate Health Care Indianapolis, Indiana
7/2012 – 12/2014	Faculty Member and Online Content Contributor www.quantiamd.com
5/2007 – 7/2007	St. Vincent Hospital Medical Education Summer Program Indianapolis, Indiana
2/2005 – 7/2006	Clinical Research Assistant Dow Agrosciences Indianapolis, Indiana

**CERTIFICATION AND LICENSURE:**

7/2013 – Present	Indiana Permanent Medical License #02004276A
10/2015 – Present	American Board of Allergy and Immunology
8/2013 – Present	American Board of Internal Medicine
5/2019 – Present	Good Clinical Practice Certification
06-2022 – Present	The Protection of Human Subjects Certification

**EDUCATION:**

Graduated 6/2010	Lake Erie College of Osteopathic Medicine, Bradenton, Florida Doctor of Osteopathy
Graduated 5/2006	Purdue University, Indianapolis, Indiana Master of Science
Graduated 12/2003	Purdue University, Indianapolis, Indiana Bachelor of Arts, Biology

MWS  
28 MAY 2026

## HONORS:

Academic Excellence Scholarship (LECOM), 2007 & 2008  
Indiana Osteopathic Association Young DO of the Year – 2020  
Indianapolis Monthly Top Doctors Award – Allergy/Immunology – 2022-2025

## POST GRADUATE TRAINING:

7/2013 – 6/2015 Allergy and Clinical Immunology  
Henry Ford Health System  
Detroit, MI

6/2010 – 6/2013 St. Vincent Health: Indianapolis, Indiana  
Internal Medicine Residency

## PROFESSIONAL SOCIETIES

2015 - Present Indiana Allergy, Asthma and Immunology Society  
President (2017), Vice President (2016)

2013 – Present American College of Allergy, Asthma and Immunology

2013 - Present American Academy of Allergy, Asthma and Immunology (Fellow)

2006 - Present Indiana Osteopathic Association

2010 - 2015 American College of Physicians

2007 - 2008 American College of Osteopathic Emergency Physicians – local chapter  
treasurer

## COMMITTEE AND VOLUNTEER EXPERIENCE

2019 AAAAI Leadership Institute

2019 – Present AAAAI Allergic Skin Diseases Committee

2010 – 2013 St Vincent Leadership series (<http://www.stvincent.org/PLS/>)

2012 – 2013 St Vincent House Staff Council – Vice President

2010 - 2013 St Vincent Recruitment Committee

2006 - 2008 Human Body Explored – high school intro to medicine course

## POSTER ABSTRACT PRESENTATIONS

**Smith M**, H. Kim, A. Sitarik, S. Havstad, G. Wegienka D. Ownby, C.C. Johnson, E. Zoratti, Early Childhood Wheezing and Asthma at 18 Years of Age. American Thoracic Society International Conference, San Diego, CA (5/2014).

**Smith M**. Heart Failure with Eosinophilia. American College of Asthma, Allergy and Immunology National Meeting, Anaheim, CA (11/2012).

**Smith M**, Mehta K. Hemophagocytosis, Crohn's Disease and Shock: A pediatric phenomenon in an immune suppressed adult. American College of Physicians Regional Meeting, Indianapolis, IN (10/2011) and National Meeting, New Orleans, LA (3/2012)

### Research

Group Visits and the Effect on Meeting Standards of Care in Diabetes. Funding Grant from the St Vincent Foundation, data presented at 2013 St Vincent research conference

## CLINICAL TRIAL EXPERIENCE

09/2019 - 2022	A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
06/2020 - 2020	A Phase 3 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy and Safety of SB206 and Vehicle Gel Once Daily in the Treatment of Molluscum Contagiosum
07/2020 – 2021	A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects with Non-Segmental Facial Vitiligo
05/2021 - 2024	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria Patients Inadequately Controlled By H1-Antihistamines
2023 – 2024	A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects with H-1 Antihistamine Refractory Chronic Spontaneous Urticaria
2024 – 2025	Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects with Chronic Spontaneous Urticaria
2024 – 2025	An Open Label Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults with Chronic Inducible Urticaria
2024 – 2026	A 12-week, Randomized, Double-Blind, Phase 4 Study Evaluating the Effect of AIRSUPRA Compared to Albuterol Administered As Needed on Changes in Airway Inflammation, Symptoms, and Rescue Therapy Utilization in Adults with Mild Asthma (DARWIN)

## CURRENT TRIALS

2023 – Present	A multicenter, double-blind, placebo-controlled, randomized withdrawal and open-label extension study followed by long-term open-label treatment cycles to assess the efficacy, safety and tolerability of remibrutinib (LOU064) in adult chronic spontaneous urticaria patients who completed the preceding remibrutinib Phase 3 studies
2024 – Present	A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in adults inadequately controlled by H1- antihistamines
2024 – Present	A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ – CSU2)


2025 – Present

A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults with Moderate to Severe Chronic Spontaneous Urticaria

2025 – Present

A Phase 2 Study to Evaluate the Safety, Tolerability, and Clinical Activity of BLU-808, a Wild Type KIT Inhibitor, in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria.

I have signed my CV to acknowledge that it is accurate, complete, and current, as of the date of signing.

Signed:  Date: 28 MAY 2026